Kidswell Bio's Days Sales Outstanding for the
six
months ended in Mar. 2026 was 65.85.
Kidswell Bio's Days Inventory for the
six
months ended in Mar. 2026 was 60.03.
Kidswell Bio's Days Payable for the
six
months ended in Mar. 2026 was 10.41.
Therefore, Kidswell Bio's Cash Conversion Cycle (CCC) for the
six
months ended in Mar. 2026 was 115.47.
Kidswell Bio (TSE:4584) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Kidswell Bio Cash Conversion Cycle Related Terms
Kidswell Bio Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Kidswell Bio's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4584 vs VRTX, REGN, ALNY: Cash Conversion Cycle Comparison
For the Biotechnology subindustry, Kidswell Bio's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kidswell Bio Cash Conversion Cycle vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kidswell Bio's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Kidswell Bio's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Kidswell Bio's Cash Conversion Cycle for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kidswell Bio (TSE:4584) has a Cash Conversion Cycle of 115.47 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Kidswell Bio and its competitors.
Is Kidswell Bio's Cash Conversion Cycle too high?
Kidswell Bio's current Cash Conversion Cycle is 115.47. The Biotechnology industry median Cash Conversion Cycle is 104.63. Kidswell Bio's value of 115.47 is 10.4% above this industry median. Overall, Kidswell Bio has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Kidswell Bio's Cash Conversion Cycle compare to VRTX and REGN?
Kidswell Bio's Cash Conversion Cycle of 115.47 can be compared against companies in the Biotechnology industry. The industry median Cash Conversion Cycle is 104.63. Kidswell Bio's value of 115.47 is 10.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Biotechnology company?
The median Cash Conversion Cycle among Biotechnology companies is 104.63, based on 868 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kidswell Bio's current Cash Conversion Cycle of 115.47 is 10.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Kidswell Bio and its competitors. For the Biotechnology industry, the median Cash Conversion Cycle is 104.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kidswell Bio's current Cash Conversion Cycle is 115.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kidswell Bio stock overvalued right now?
Based on GuruFocus' analysis, Kidswell Bio (TSE:4584) is currently considered Possible Value Trap. The stock's GF Value™ is 円233.48, compared to a current price of 円156.00 — trading 33.2% below its estimated fair value. The current Cash Conversion Cycle is 115.47 and 10.4% above the Biotechnology industry median of 104.63. Kidswell Bio's overall GF Score™ is 48/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Kidswell Bio (TSE:4584), the current Cash Conversion Cycle is 115.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kidswell Bio (TSE:4584) Overvalued in 2026?
Based on GuruFocus' analysis, Kidswell Bio stock appears to be undervalued.
The current stock price of 円156.00 is trading 33.2% below its estimated GF Value™ of 円233.48.
GuruFocus considers Kidswell Bio to be Possible Value Trap.
Key valuation signals for TSE:4584:
Cash Conversion Cycle: 115.47
GF Value™: 円233.48 vs. price of 円156.00 (33.2% below fair value)
Industry Position: 10.4% above the Biotechnology median
No single metric tells the full story. See the TSE:4584 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4584 has been successfully added to your 
